Institute of Global Health Innovation, Department of Surgery and Cancer, Imperial College London, London, UK.
Institute of Global Health Innovation, Department of Surgery and Cancer, Imperial College London, London, UK; Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's Clinical Trials Unit, King's College London, London, UK.
Lancet Digit Health. 2022 Sep;4(9):e646-e656. doi: 10.1016/S2589-7500(22)00123-6. Epub 2022 Jul 28.
Accurate assessment of COVID-19 severity in the community is essential for patient care and requires COVID-19-specific risk prediction scores adequately validated in a community setting. Following a qualitative phase to identify signs, symptoms, and risk factors, we aimed to develop and validate two COVID-19-specific risk prediction scores. Remote COVID-19 Assessment in Primary Care-General Practice score (RECAP-GP; without peripheral oxygen saturation [SpO]) and RECAP-oxygen saturation score (RECAP-O2; with SpO).
RECAP was a prospective cohort study that used multivariable logistic regression. Data on signs and symptoms (predictors) of disease were collected from community-based patients with suspected COVID-19 via primary care electronic health records and linked with secondary data on hospital admission (outcome) within 28 days of symptom onset. Data sources for RECAP-GP were Oxford-Royal College of General Practitioners Research and Surveillance Centre (RCGP-RSC) primary care practices (development set), northwest London primary care practices (validation set), and the NHS COVID-19 Clinical Assessment Service (CCAS; validation set). The data source for RECAP-O2 was the Doctaly Assist platform (development set and validation set in subsequent sample). The two probabilistic risk prediction models were built by backwards elimination using the development sets and validated by application to the validation datasets. Estimated sample size per model, including the development and validation sets was 2880 people.
Data were available from 8311 individuals. Observations, such as SpO, were mostly missing in the northwest London, RCGP-RSC, and CCAS data; however, SpO was available for 1364 (70·0%) of 1948 patients who used Doctaly. In the final predictive models, RECAP-GP (n=1863) included sex (male and female), age (years), degree of breathlessness (three point scale), temperature symptoms (two point scale), and presence of hypertension (yes or no); the area under the curve was 0·80 (95% CI 0·76-0·85) and on validation the negative predictive value of a low risk designation was 99% (95% CI 98·1-99·2; 1435 of 1453). RECAP-O2 included age (years), degree of breathlessness (two point scale), fatigue (two point scale), and SpO at rest (as a percentage); the area under the curve was 0·84 (0·78-0·90) and on validation the negative predictive value of low risk designation was 99% (95% CI 98·9-99·7; 1176 of 1183).
Both RECAP models are valid tools to assess COVID-19 patients in the community. RECAP-GP can be used initially, without need for observations, to identify patients who require monitoring. If the patient is monitored and SpO is available, RECAP-O2 is useful to assess the need for treatment escalation.
Community Jameel and the Imperial College President's Excellence Fund, the Economic and Social Research Council, UK Research and Innovation, and Health Data Research UK.
准确评估社区内 COVID-19 的严重程度对于患者的治疗至关重要,这需要 COVID-19 特异性风险预测评分在社区环境中得到充分验证。在进行了定性阶段以确定体征、症状和危险因素之后,我们旨在开发和验证两个 COVID-19 特异性风险预测评分。远程 COVID-19 初级保健-全科医学评估评分(RECAP-GP;不包括外周血氧饱和度[SpO])和 RECAP-血氧饱和度评分(RECAP-O2;包括 SpO)。
RECAP 是一项前瞻性队列研究,使用多变量逻辑回归。通过初级保健电子健康记录从疑似 COVID-19 的社区患者中收集疾病的体征和症状(预测因素)数据,并将其与发病后 28 天内的住院(结局)的二级数据相关联。RECAP-GP 的数据源是牛津-皇家全科医师学院研究和监测中心(RCGP-RSC)初级保健实践(开发集)、伦敦西北部初级保健实践(验证集)和 NHS COVID-19 临床评估服务(CCAS;验证集)。RECAP-O2 的数据源是 Doctaly Assist 平台(开发集和随后的样本中的验证集)。这两个概率风险预测模型通过向后消除法使用开发集构建,并通过在验证数据集上的应用进行验证。每个模型的估计样本量(包括开发集和验证集)为 2880 人。
从 8311 个人中获得了数据。观察值,如 SpO,在伦敦西北部、RCGP-RSC 和 CCAS 数据中大多缺失;然而,Doctaly 使用的 1948 名患者中有 1364 名(70.0%)提供了 SpO。在最终的预测模型中,RECAP-GP(n=1863)包括性别(男性和女性)、年龄(岁)、呼吸困难程度(三分制)、体温症状(二分制)和高血压存在情况(是或否);曲线下面积为 0.80(95%CI 0.76-0.85),在验证中,低风险指定的阴性预测值为 99%(95%CI 98.1-99.2;1435 例中的 1453 例)。RECAP-O2 包括年龄(岁)、呼吸困难程度(二分制)、疲劳(二分制)和休息时的 SpO(百分比);曲线下面积为 0.84(0.78-0.90),在验证中,低风险指定的阴性预测值为 99%(95%CI 98.9-99.7;1176 例中的 1183 例)。
这两个 RECAP 模型都是评估社区内 COVID-19 患者的有效工具。RECAP-GP 可以首先使用,无需观察,以识别需要监测的患者。如果患者得到监测并且可以获得 SpO,那么 RECAP-O2 可用于评估是否需要升级治疗。
社区贾米尔和帝国学院校长卓越基金、英国经济与社会研究理事会、英国研究与创新署以及英国健康数据研究署。